宏量营养素补充剂对早产儿或小于胎龄儿后期生长的影响:随机和准随机对照试验的系统评价和荟萃分析。
Impact of macronutrient supplements on later growth of children born preterm or small for gestational age: A systematic review and meta-analysis of randomised and quasirandomised controlled trials.
机构信息
Liggins Institute, University of Auckland, Auckland, New Zealand.
出版信息
PLoS Med. 2020 May 26;17(5):e1003122. doi: 10.1371/journal.pmed.1003122. eCollection 2020 May.
BACKGROUND
Nutritional supplements may improve short-term growth of infants born small (preterm or small for gestational age), but there are few data on long-term effects and concerns that body composition may be adversely affected. Effects also may differ between girls and boys. Our systematic review and meta-analysis assessed the effects of macronutrient supplements for infants born small on later growth.
METHODS AND FINDINGS
We searched OvidMedline, Embase, Cochrane CENTRAL, and Cochrane Database of Systematic Reviews from inception to January 30, 2020, and controlled-trials.com, clinicaltrials.gov, and anzctr.org.au on January 30, 2020. Randomised or quasirandomised trials were included if the intention was to increase macronutrient intake to improve growth or development of infants born small and growth was assessed after discharge. Primary outcome was body mass index (BMI) in childhood. Data were pooled using random-effect models. Outcomes were evaluated in toddlers (< 3 years), childhood (3 to 8 years), adolescence (9 to 18 years), and adulthood (>18 years). Forty randomised and 2 quasirandomised trials of variable methodological quality with 4,352 infants were included. Supplementation did not alter BMI in childhood (7 trials, 1,136 children; mean difference [MD] -0.10 kg/m2, [95% confidence interval (CI) -0.37 to 0.16], p = 0.45). In toddlers, supplementation increased weight (31 trials, 2,924 toddlers; MD 0.16 kg, [0.01 to 0.30], p = 0.03) and length/height (30 trials, 2,889 toddlers; MD 0.44 cm, [0.10 to 0.77], p = 0.01), but not head circumference (29 trials, 2,797 toddlers; MD 0.15 cm, [-0.03 to 0.33], p = 0.10). In childhood, there were no significant differences between groups in height (7 trials, 1,136 children; MD 0.22 cm, [-0.48 to 0.92], p = 0.54) or lean mass (3 trials, 354 children; MD -0.07 kg, [-0.98 to 0.85], p = 0.88), although supplemented children appeared to have higher fat mass (2 trials, 201 children; MD 0.79 kg, [0.19 to 1.38], p = 0.01). In adolescence, there were no significant differences between groups in BMI (2 trials, 216 adolescents; MD -0.48 kg/m2, [-2.05 to 1.08], p = 0.60), height (2 trials, 216 adolescents; MD -0.55 cm, [-2.95 to 1.86], p = 0.65), or fat mass (2 trials, 216 adolescents; MD -1.3 5 kg, [-5.76 to 3.06], p = 0.55). In adulthood, there also were no significant differences between groups in weight z-score (2 trials, 199 adults; MD -0.11, [-0.72 to 0.50], p = 0.73) and height z-score (2 trials, 199 adults; MD -0.07, [-0.36 to 0.22], p = 0.62). In subgroup analysis, supplementation was associated with increased length/height in toddler boys (2 trials, 173 boys; MD 1.66 cm, [0.75 to 2.58], p = 0.0003), but not girls (2 trials, 159 girls; MD 0.15 cm, [-0.71 to 1.01], p = 0.74). Limitations include considerable unexplained heterogeneity, low to very low quality of evidence, and possible bias due to low or unbalanced followup.
CONCLUSIONS
In this systematic review and meta-analysis, we found no evidence that early macronutrient supplementation for infants born small altered BMI in childhood. Although supplements appeared to increase weight and length in toddlers, effects were inconsistent and unlikely to be clinically significant. Limited data suggested that supplementation increased fat mass in childhood, but these effects did not persist in later life. PROSPERO registration: CRD42019126918.
背景
营养补充剂可能会改善出生时较小的婴儿(早产或小于胎龄)的短期生长,但关于长期影响的数据很少,而且人们担心身体成分可能会受到不利影响。女孩和男孩之间的效果也可能不同。我们的系统评价和荟萃分析评估了为出生较小的婴儿提供宏量营养素补充剂对后期生长的影响。
方法和发现
我们检索了 OvidMedline、Embase、Cochrane CENTRAL 和 Cochrane 系统评价数据库,从建库到 2020 年 1 月 30 日,并于 2020 年 1 月 30 日检索了 controlled-trials.com、clinicaltrials.gov 和 anzctr.org.au。如果意图是增加宏量营养素的摄入以改善出生较小的婴儿的生长或发育,且在出院后评估生长情况,则纳入随机或半随机试验。主要结局是儿童期的体重指数(BMI)。使用随机效应模型汇总数据。评估了幼儿期(<3 岁)、儿童期(3-8 岁)、青春期(9-18 岁)和成年期(>18 岁)的结果。纳入了 40 项随机和 2 项半随机试验,涉及 4352 名婴儿,这些试验具有不同的方法学质量。补充剂并未改变儿童期的 BMI(7 项试验,1136 名儿童;MD-0.10kg/m2,[95%置信区间(CI)-0.37 至 0.16],p=0.45)。在幼儿期,补充剂增加了体重(31 项试验,2924 名幼儿;MD 0.16kg,[0.01 至 0.30],p=0.03)和身高(30 项试验,2889 名幼儿;MD 0.44cm,[0.10 至 0.77],p=0.01),但头围无变化(29 项试验,2797 名幼儿;MD 0.15cm,[-0.03 至 0.33],p=0.10)。在儿童期,两组之间的身高(7 项试验,1136 名儿童;MD 0.22cm,[-0.48 至 0.92],p=0.54)或瘦体重(3 项试验,354 名儿童;MD-0.07kg,[-0.98 至 0.85],p=0.88)无显著差异,尽管补充组的脂肪量似乎更高(2 项试验,201 名儿童;MD 0.79kg,[0.19 至 1.38],p=0.01)。在青春期,两组之间的 BMI(2 项试验,216 名青少年;MD-0.48kg/m2,[-2.05 至 1.08],p=0.60)、身高(2 项试验,216 名青少年;MD-0.55cm,[-2.95 至 1.86],p=0.65)或脂肪量(2 项试验,216 名青少年;MD-1.35kg,[-5.76 至 3.06],p=0.55)均无显著差异。在成年期,两组之间的体重 z 评分(2 项试验,199 名成年人;MD-0.11,[-0.72 至 0.50],p=0.73)和身高 z 评分(2 项试验,199 名成年人;MD-0.07,[-0.36 至 0.22],p=0.62)也无显著差异。亚组分析显示,补充剂与男童(2 项试验,173 名男童;MD 1.66cm,[0.75 至 2.58],p=0.0003)的身高增长有关,但与女童(2 项试验,159 名女童;MD 0.15cm,[-0.71 至 1.01],p=0.74)无关。局限性包括相当大的无法解释的异质性、证据的质量低至非常低,以及由于随访低或不平衡而可能存在的偏倚。
结论
在这项系统评价和荟萃分析中,我们没有发现早期为出生较小的婴儿提供宏量营养素补充剂会改变儿童期的 BMI。尽管补充剂似乎增加了幼儿期的体重和身高,但这些影响不一致,不太可能具有临床意义。有限的数据表明,补充剂增加了儿童期的脂肪量,但这些影响在以后的生活中并未持续。PROSPERO 注册:CRD42019126918。